Korsana Biosciences, Inc. (KRSA): Cash & Equivalents
$3.24M
As of 2025-12-31
$1.39M
As of 2026-06-30
-37.7%
3-year compound annual growth
-43.1%
5-year compound annual growth
| Period ended | Cash & Equivalents | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $3.24M | +0.2% | 2026-03-30, Balance as of period end |
| 2024-12-31 | $3.23M | -57.3% | 2026-03-30, Balance as of period end |
| 2023-12-31 | $7.57M | -43.4% | 2025-11-12, Balance as of period end |
| 2022-12-31 | $13.38M | -75.2% | 2024-03-05, Balance as of period end |
| 2021-12-31 | $53.96M | -0.8% | 2023-03-22, Balance as of period end |
| 2020-12-31 | $54.40M | -42.7% | 2022-02-24, Balance as of period end |
| 2019-12-31 | $94.89M | n/a | 2021-02-25, Balance as of period end |
Cash & Equivalents at similar companies
| Company | Year ended | Cash & Equivalents | Change YoY |
|---|---|---|---|
| Korsana Biosciences, Inc. (KRSA) | 2025-12-31 | $3.24M | +0.2% |
| Dianthus Therapeutics, Inc. (DNTH) | 2025-12-31 | $51.09M | +124.1% |
| Lipocine Inc. (LPCN) | 2025-12-31 | $5.21M | -16.1% |
| Bio Essence Corp (BIOE) | 2024-12-31 | $1.4K | n/m |
| GeoVax Labs, Inc. (GOVX) | 2025-12-31 | $3.09M | -44.0% |
| Rani Therapeutics Holdings, Inc. (RANI) | 2025-12-31 | $18.62M | +394.9% |
| Cartesian Therapeutics, Inc. (RNAC) | 2025-12-31 | $125.14M | -41.1% |
| Upstream Bio, Inc. (UPB) | 2025-12-31 | $101.58M | -68.8% |
| NRX Pharmaceuticals, Inc. (NRXP) | 2025-12-31 | $7.80M | +440.3% |
Compare KRSA, DNTH, LPCN, BIOE side by side · Screen every company in Pharmaceutical Preparations ↗